<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016041</url>
  </required_header>
  <id_info>
    <org_study_id>NL15206.101.06</org_study_id>
    <nct_id>NCT01016041</nct_id>
  </id_info>
  <brief_title>A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial</brief_title>
  <acronym>COMPARE 1</acronym>
  <official_title>A Randomized Controlled Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maasstad Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Instead of treating in-stent restenosis, the best strategy for patients is preventing&#xD;
      in-stent restenosis. Recent advances in the understanding of the cellular mechanism&#xD;
      responsible for smooth muscle cell proliferation (neointimal hyperplasia), together with&#xD;
      improvement in stent coating and eluting technology have provided the scientific background&#xD;
      to develop drug eluting stents. Drug eluting stents (DES) are now the most promising&#xD;
      development in interventional cardiology. Different classes of drugs mounted in a polymer&#xD;
      layer on the surface of the stent have shown to be very effective in preventing neointimal&#xD;
      hyperplasia. Currently there are 7 DES stents CE marked and commercially available on the&#xD;
      market. Two stents, respectively the sirolimus eluting Cypher™ stent and the paclitaxel&#xD;
      eluting Taxus™ stent, are in clinical use since 2002. The Cypher™ stent consists of the Bx&#xD;
      sonic stent/balloon platform. The stent is coated with a non-degradable biocompatible&#xD;
      PBMA/PEVA polymer which elutes sirolimius. The Taxus™ stent consists of the Express2&#xD;
      balloon/stent platform coated with non-degradable biocompatible Translute™ polymer which&#xD;
      elutes paclitaxel.&#xD;
&#xD;
      Recent large randomized trials like RAVEL, SIRIUS, E-SIRIUS C-SIRIUS (Cypher™ versus bare&#xD;
      metal BX sonic™ stent), TAXUS II, IV, V, VI (Taxus versus bare metal Express™ stent) have&#xD;
      shown that DES dramatically reduce the incidence of in-stent restenosis and subsequently the&#xD;
      need for target lesion revascularization in patients with non complex and moderate long&#xD;
      de-novo coronary lesions in vessels with a diameter between 2.5 -3.5 mm.1-11 Considering the&#xD;
      very encouraging results of these early clinical trials with so far mid long term follow-up,&#xD;
      there is the need to explore the utilization of DES in the other subsets of coronary lesions&#xD;
      like: long lesions, chronic total occlusions, venous graft lesions, thrombotic lesions,&#xD;
      restenosis lesions, ostial and bifurcation lesions and lesions in large vessels.&#xD;
&#xD;
      As the result from the previous reported randomized trials, FDA and other regulatory&#xD;
      institutes require that new DES are now being evaluated against one of the former DES (Cypher&#xD;
      or Taxus). The XIENCE-V stent is a second generation DES, with thinner and more flexible&#xD;
      Cobalt-Chromium stent struts, compared to the first generation Stainless Steel stent struts&#xD;
      of Cypher and Taxus. This study addresses the questions whether the XIENCE-V™ stent has&#xD;
      superior clinical results as the Taxus™ stent in the general population that is being&#xD;
      referred for percutaneous coronary intervention (PCI).&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      The main objective of the study is a head tot head comparison of the everolimus coated&#xD;
      XIENCE-V™ stent with the paclitaxel coated TAXUS™ stent in order to observe whether there is&#xD;
      a difference in clinical outcome between both stents.&#xD;
&#xD;
      Efficacy of both stents will be assessed by the composite end point of: all death, non fatal&#xD;
      myocardial infarction and target vessel revascularization.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Single center, randomised, open label study in all-comers referred for PCI.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Approximately 1600 consecutive patients with coronary artery disease who are eligible&#xD;
      according to the in- and exclusion criteria will be enrolled and randomized on a 1:1 basis.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      The primary end point of the study is the composite end point of: all death, non fatal&#xD;
      myocardial infarction, target vessel revascularization at 1 year.&#xD;
&#xD;
      Secondary study parameters/outcome of the study:&#xD;
&#xD;
      The secondary end points of the study are:&#xD;
&#xD;
      A) The combined endpoint of cardiac death, non fatal myocardial infarction, ischemic driven&#xD;
      target lesion revascularization (TLR) rate at 1, 6 and 12 months follow-up.&#xD;
&#xD;
      B) The combined endpoint of all death, non fatal myocardial infarction, target vessel&#xD;
      revascularization (TVR) rate at 2, 3, 4 and 5 years.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness:&#xD;
&#xD;
      The burden for the patient consists of filling in 8 questionnaires (1 A4 per questionnaire)&#xD;
      in 5 years time.&#xD;
&#xD;
      The first 3 questionnaires in the first year are also requested for monitoring purposes by&#xD;
      the Ministry of Health and the Dutch Cardiology Society (Nederlandse Vereniging Voor&#xD;
      Cardiologie; NVVC).&#xD;
&#xD;
      There is no risk for the patient related to participation in this study. The patient will&#xD;
      receive a Taxus or Xience-V stent anyhow, if the indication for a DES stent exists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the study is the composite end point of: all death, non fatal myocardial infarction, target vessel revascularization at 1 year.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The combined endpoint of cardiac death, non fatal myocardial infarction, ischemic driven target lesion revascularization (TLR) rate at 1, 6 and 12 months follow-up.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1800</enrollment>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>everolimus stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel eluting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>everolimus stent</intervention_name>
    <description>stenting</description>
    <arm_group_label>everolimus stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel stent</intervention_name>
    <description>stenting</description>
    <arm_group_label>paclitaxel eluting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient from 18 to 85 years with lesions feasible for PCI treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dual antiplatelet therapy contraindication,&#xD;
&#xD;
          -  Participation in other trials,&#xD;
&#xD;
          -  No informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>December 24, 2015</last_update_submitted>
  <last_update_submitted_qc>December 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <name_title>Pieter Smits</name_title>
    <organization>Maasstad Hospital</organization>
  </responsible_party>
  <keyword>drug-eluting stent</keyword>
  <keyword>stable angina</keyword>
  <keyword>ACS</keyword>
  <keyword>MACE</keyword>
  <keyword>safety</keyword>
  <keyword>stent thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

